Literature DB >> 11163778

The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia.

A Bertolino1, J H Callicott, V S Mattay, K M Weidenhammer, R Rakow, M F Egan, D R Weinberger.   

Abstract

BACKGROUND: The specific intracellular effects of antipsychotic drugs are largely unknown. Studies in animals have suggested that antipsychotics modify the expression of various intraneuronal proteins, but no analogous in vivo data in humans are available. The objective of the present study was to assess whether antipsychotics modify N-acetylaspartate (an intraneuronal marker of neuronal functional integrity) measures in brains of patients with schizophrenia.
METHODS: We used proton magnetic resonance spectroscopic imaging to study 23 patients with schizophrenia (DSM-IV diagnosis) using a within-subject design. Patients were studied twice: once while on a stable regimen of antipsychotic drug treatment (for at least 4 weeks) and once while off medication for at least 2 weeks. Several cortical and subcortical regions were assessed, including the dorsolateral prefrontal cortex and the hippocampal area.
RESULTS: Analysis of variance showed that, while on antipsychotics, patients had significantly higher N-acetylaspartate measures in the dorsolateral prefrontal cortex (p =.002). No other region showed any significant effect of treatment.
CONCLUSIONS: These results indicate that antipsychotic drugs increase N-acetylaspartate measures selectively in the dorsolateral prefrontal cortices of patients with schizophrenia, suggesting that these drugs modify in a regionally specific manner the function of a population of cortical neurons. N-Acetylaspartate measures may provide a useful tool to further investigate the effects of antipsychotics at the intracellular level.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11163778     DOI: 10.1016/s0006-3223(00)00997-5

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  39 in total

Review 1.  [Genetic and pharmacological effects on prefrontal cortical function in schizophrenia].

Authors:  Andreas Heinz; Dieter F Braus; Berenice Romero; Jürgen Gallinat; Imke Puls; Georg Juckel; Daniel R Weinberger
Journal:  Nervenarzt       Date:  2004-09       Impact factor: 1.214

Review 2.  [One decade of functional imaging in schizophrenia research. From visualisation of basic information processing steps to molecular-genetic oriented imaging].

Authors:  H Tost; A Meyer-Lindenberg; M Ruf; T Demirakça; O Grimm; F A Henn; G Ende
Journal:  Radiologe       Date:  2005-02       Impact factor: 0.635

Review 3.  N-acetylaspartate as a marker of neuronal injury in neurodegenerative disease.

Authors:  Norbert Schuff; Dieter J Meyerhoff; Susanne Mueller; Linda Chao; Diana Truran Sacrey; Kenneth Laxer; Michael W Weiner
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

Review 4.  Imaging genomics and response to treatment with antipsychotics in schizophrenia.

Authors:  Giuseppe Blasi; Alessandro Bertolino
Journal:  NeuroRx       Date:  2006-01

Review 5.  Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders.

Authors:  Stephen R Dager; Neva M Corrigan; Todd L Richards; Stefan Posse
Journal:  Top Magn Reson Imaging       Date:  2008-04

Review 6.  Neuroimaging markers of antipsychotic treatment response in schizophrenia: An overview of magnetic resonance imaging studies.

Authors:  Goda Tarcijonas; Deepak K Sarpal
Journal:  Neurobiol Dis       Date:  2018-06-25       Impact factor: 5.996

7.  Decreased hippocampal N-acetylaspartate in the absence of atrophy in posttraumatic stress disorder.

Authors:  N Schuff; T C Neylan; M A Lenoci; A T Du; D S Weiss; C R Marmar; M W Weiner
Journal:  Biol Psychiatry       Date:  2001-12-15       Impact factor: 13.382

8.  Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.

Authors:  L Fredrik Jarskog; Zhengchao Dong; Alayar Kangarlu; Tiziano Colibazzi; Ragy R Girgis; Lawrence S Kegeles; Deanna M Barch; Robert W Buchanan; John G Csernansky; Donald C Goff; Michael P Harms; Daniel C Javitt; Richard Se Keefe; Joseph P McEvoy; Robert P McMahon; Stephen R Marder; Bradley S Peterson; Jeffrey A Lieberman
Journal:  Neuropsychopharmacology       Date:  2013-01-16       Impact factor: 7.853

9.  Cholinergic dysfunction in fragile X syndrome and potential intervention: a preliminary 1H MRS study.

Authors:  Shelli R Kesler; Amy A Lightbody; Allan L Reiss
Journal:  Am J Med Genet A       Date:  2009-03       Impact factor: 2.802

Review 10.  The neurotrophic and neuroprotective effects of psychotropic agents.

Authors:  Joshua Hunsberger; Daniel R Austin; Ioline D Henter; Guang Chen
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.